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Microglial Inﬂammation and Cognitive Dysfunction in Comorbid Rat
Models of Striatal Ischemic Stroke and Alzheimer’s Disease: Eﬀects of
Antioxidant Catalase-SKL on Behavioral and Cellular Pathology
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Abstract—Ischemic stroke often co-occurs with Alzheimer’s disease (AD) leading to a worsened clinical outcome.
Neuroinﬂammation is a critical process implicated in AD and ischemic pathology, associated with cognitive
decline. We sought to investigate the combined eﬀects of ischemic stroke induced by endothelin-1 injection in
two AD rat models, using motor function, memory and microglial inﬂammation in the basal forebrain and striatum
as readouts. In addition, we sought to determine the eﬀectiveness of the antioxidant biologic CAT-SKL in one of
the models. The early AD model employed the bilateral intracerebroventricular injections of the toxic b-amyloid
peptide Ab25–35, the prodromal AD model used the transgenic Fischer 344 rat overexpressing a pathological
mutant human amyloid precursor protein. Motor function was assessed using a cylinder, modiﬁed sticky tape
and beam-walk tasks; learning and memory were tested in the Morris water maze. Microglial activation was examined using immunohistochemistry. Ab25–35 toxicity and stroke combination greatly increased microglial inﬂammation in the basal forebrain. Prodromal AD-pathology coupled with ischemia in the transgenic rat resulted in a
greater microgliosis in the striatum. Combined transgenic rats showed balance alterations, comorbid Ab25–35 rats
showed a transient sensorimotor deﬁcit, and both demonstrated spatial reference memory deﬁcit. CAT-SKL treatment ameliorated memory impairment and basal forebrain microgliosis in Ab25–35 rats with stroke. Our results
suggest that neuroinﬂammation could be one of the early processes underlying the interaction of AD with stroke
and contributing to the cognitive impairment, and that therapies such as antioxidant CAT-SKL could be a potential therapeutic strategy. Ó 2022 The Author(s). Published by Elsevier Ltd on behalf of IBRO. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Key words: comorbidity, memory, neuroinﬂammation, microglia activation, oxidative stress, catalase.

INTRODUCTION
Alzheimer’s disease (AD), the most prevalent type of
dementia, and ischemic stroke are very common
disorders aﬀecting a large proportion of the world’s
population. In a large number of cases dementia,
including AD, and stroke coincide. The prevalence of
stroke comorbidity with dementia among Canadians
aged 65 years and older was 1.8%, or 110,000 people,
in 2016–2017 (Public Health Agency of Canada, 2020).
In the US, the comorbidity of self-reported cognitive
decline with stroke in a same age group and similar time
period was reported to be 15% (Taylor et al., 2020). Moreover, an interaction between cerebral ischemia and AD
pathologies
was
suggested
by
epidemiological
(Tatemichi et al., 1992; Snowdon, 1997; Esiri et al.,
1999; Vermeer et al., 2003; Regan et al., 2006;
Cechetto et al., 2008; Thiel et al., 2014; Zhou et al.,
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(S. N. Whitehead), cechetto@uwo.ca (D. F. Cechetto).
Abbreviations: Ab, amyloid-b; AAF, attending aﬀected forelimb score;
AD, Alzheimer’s disease; AFU, aﬀected forelimb use score; AP,
anterior–posterior; APP, amyloid precursor protein; ANOVA, analysis
of variance; CAT-SKL, genetically engineered cell penetrating variant
of catalase with a serine-lysine-leucine carboxy terminal consensus
sequence; DV, dorsal–ventral; ET-1, endothelin-1; H2O2, hydrogen
peroxide; ICV, intracerebroventricular; ID, rat identity; MHC, major
histocompatibility complex; ML, medial–lateral; MST, modiﬁed sticky
tape task; MWM, Morris water maze; PCR, polymerase chain reaction;
ROI, region of interest; ROS, reactive oxygen species; RP, reverse
peptide (Ab35–25); Sal, 0.9% saline; TG, transgenic (Fischer 344
APP21 rat); TZ, target zone used to contain the hidden platform during
the learning phase; WT, wildtype (Fischer 344 rat).
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2014)and clinicopathological studies (Snowdon, 1997;
Kalaria, 2000; Del Ser et al., 2005; Schneider et al.,
2007; Cechetto et al., 2008; Toledo et al., 2013; Attems
and Jellinger, 2014)and further supported by ﬁndings from
research animal models (Whitehead et al., 2005;
Whitehead et al., 2005; Whitehead et al., 2007;
Whitehead et al., 2010; Amtul et al., 2015; Madigan
et al., 2016; Levit et al., 2017). Especially microinfarcts,
such as striatal lacunar infarcts, were found to exacerbate
cognitive symptoms in individuals with dementia as well
as worsen cognitive performance in combined rodent
models of AD and cerebral ischemia (Heyman et al.,
1998; Esiri et al., 1999; Whitehead et al., 2005;
Whitehead et al., 2005; Whitehead et al., 2007;
Whitehead et al., 2010; Amtul et al., 2014; Levit et al.,
2017). Neuroinﬂammation and oxidative stress, two processes implicated in the pathogenesis of both AD
(Akiyama, 2000; McGeer and McGeer, 2003; WyssCoray, 2006; Venkateshappa et al., 2012; Fischer and
Maier, 2015; Wojsiat et al., 2018)and brain injury after
ischemic stroke (Nogawa et al., 1997; Stoll et al., 1998;
Allen and Bayraktutan, 2009; Lakhan et al., 2009; Thiel
et al., 2010; Weinstein et al., 2010), were proposed key
events underlying the interaction between these disorders
from the early disease stage and contributing to the cognitive impairment (Whitehead et al., 2005; Whitehead
et al., 2007; Amtul et al., 2015; Amtul, 2015).
Chronic dysregulated neuroinﬂammation is one of the
critical components in the pathogenesis of AD with
microglia being one of the key cellular players in the
inﬂammatory cascade (Kinney et al., 2018). Microglial
cells respond to brain insults by releasing proinﬂammatory cytotoxic factors and generating reactive
oxygen species (ROS) which contributes to the brain tissue damage and neuronal degeneration when this
response is not quickly resolved (Heneka et al., 2015).
Oxidative stress is evoked by an imbalance in ROS production and the counteracting capabilities of the antioxidant mechanisms of the cell. Accumulation of the
amyloid-b (Ab) protein produced from the amyloid precursor protein (APP), one of the hallmark pathologies in AD,
is a potent trigger of ROS and cytokine generation by
microglia (Bales et al., 2000; Combs et al., 2001). In turn,
ROS activate glial cells to further feed the oxidative environment and potentiate neuroinﬂammation ultimately
propagating the damage. These events appear very early
in the prodromal AD stage, far preceding amyloid plaque
pathology and highlight a promising treatment avenue
(Akiyama, 2000; Nunomura et al., 2001; Wyss-Coray,
2006; Heneka et al., 2015; Kinney et al., 2018). Similar
inﬂammatory and oxidative pathology with profound glial
involvement is also implicated in response to ischemia
and brain injury (Nogawa et al., 1997; Stoll et al., 1998;
Allen and Bayraktutan, 2009; Lakhan et al., 2009; Thiel
et al., 2010; Weinstein et al., 2010).
Cholinergic neurons of the basal forebrain region that
are essential for normal cognitive functioning were found
to be especially susceptible to oxidative damage early in
AD (Whitehouse et al., 1982; Collerton, 1989; Auld
et al., 2002; Kadowaki et al., 2005; Schliebs, 2005;
Geula et al., 2008; Craig et al., 2011). The previous work

of our team has demonstrated a cholinergic loss in the
basal forebrain which was correlated with increased
microglial activation in that region and accompanied by
a memory impairment in the Ab25–35 – injected rat model
of late-onset sporadic AD (Nell et al., 2015; Nell et al.,
2017). These eﬀects of the Ab toxicity were successfully
counteracted by targeted treatment with the antioxidant
biologic CAT-SKL (Nell et al., 2017), a genetically engineered cell penetrating variant of the antioxidant enzyme
catalase targeted to the cell peroxisomes by virtue of a
more eﬃcient peroxisomal targeting signal. Treatment
with CAT-SKL has been previously shown to be eﬀective
in various in vitro models of disease (Wood et al., 2006;
Koepke et al., 2007; Young et al., 2008; Undyala et al.,
2011; Giordano and Terlecky, 2012; Giordano et al.,
2015). Collectively, these ﬁndings support the use of the
CAT-SKL as a promising therapeutic strategy for disorders with increased oxidative stress and neuroinﬂammation including AD and cerebral ischemia.
The current study was set to ﬁrst examine the eﬀect of
the comorbidity of striatal ischemic stroke and AD-related
brain pathologies on motor function, memory and
microglial activation speciﬁcally in the basal forebrain
and striatum regions. We next examined whether the
CAT-SKL antioxidant therapy is able to ameliorate the
exacerbated inﬂammatory pathology and cognitive
deﬁcit in the case of comorbidity of cerebral amyloid
toxicity with stroke.
We used two previously established rat models of AD
in this study. The ﬁrst model was developed by
intracerebroventricular (ICV) injections of neurotoxic
Ab25–35 peptide creating a complex neuropathological
environment of the early-stages of human late-onset
sporadic AD including increased neuroinﬂammation,
cholinergic dysfunction and multi-regional neuronal loss
which is accompanied by a memory impairment
(Whitehead et al., 2005; Cheng et al., 2006; Whitehead
et al., 2007; Zussy et al., 2011; Zussy et al., 2013; Yang
et al., 2014; Amtul et al., 2015; Amtul, 2015; Nell et al.,
2015; Nell et al., 2017). Since the initial in vivo CATSKL study was performed employing this AD model
(Nell et al., 2017), it was used for the current investigation
of the CAT-SKL treatment eﬀects. The second model was
a novel APP21 transgenic (TG) Fischer 344 rat overexpressing mutant human APP with Swedish and Indiana
mutations implicated in the familial variant of AD (Agca
et al., 2008; Silverberg et al., 2015; Au et al., 2016;
Levit et al., 2017; Caughlin et al., 2018; Klakotskaia
et al., 2018; Weishaupt et al., 2018; Levit et al., 2019;
Ivanova et al., 2020; Levit et al., 2020). This rat does
not show spontaneous amyloid plaque formation or neuron loss with age, but develops an age-related increase
in white matter microglial activation and cognitive
changes in the executive and memory domains, thus,
recreating the prodromal stage of AD (Baudic et al.,
2006; Grober et al., 2008; Prins and Scheltens, 2015;
Lee et al., 2016). The small ischemic stroke mimicking
conditions seen in humans was induced in both AD models by a unilateral striatal endothelin-1 (ET-1) injection
which
causes
focal
cerebral
vasoconstriction
(Yanagisawa et al., 1988).
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The results indicate only a transient forelimb ﬁne
motor deﬁcit seen in the Ab25–35-injected rats with ET-1
stroke. The signs of a potential balance disturbance
were observed in the combined APP21 TG with stroke
rats. Both comorbid rats developed a spatial memory
impairment on the Morris water maze (MWM) probe trial
where an increased latency to ﬁrst entry to the target
zone was observed. The behavioral methods and
representative results of the APP21 TG model were
originally presented by supplementary video in (Au
et al., 2016) and the results are comprehensively discussed in the current manuscript. Microglial activation
was signiﬁcantly increased in the basal forebrain region
of the Ab25–35 – injected rats combined with striatal stroke
and, on the contrary, only in the striatal infarct area of the
ET-1 – injected APP21 TG Fischer 344 rats. The CATSKL treatment demonstrated eﬃcacy in preventing basal
forebrain microgliosis and cognitive deﬁcit under conditions of concurrent stroke and cerebral amyloid toxicity
in the Ab25–35-injected rats with stroke. These results further support the role of microglial-mediated inﬂammation
in the interaction between cerebral ischemia and AD
and their implication in the cognitive impairment beginning
as early as the prodromal stage of AD.

EXPERIMENTAL PROCEDURES
Animals and models
All animal handling and procedures were performed in
accordance with the Canadian Council on Animal Care
guidelines and with approval from the Western
University Animal Care Committee (AUP 2008-113;
AUP 2014-016). All eﬀorts were made to reduce the
numbers of animals used and to minimize their
suﬀering. Male Wistar rats were obtained from Charles
River Laboratories (Montreal, QC). Original breeding
pairs of male Fischer 344 wildtype (WT) and APP21 TG
rats were obtained from Drs. Yuksel Agca and Cansu
Agca (University of Missouri, Colombia, MO, USA)
(Agca et al., 2008) and subsequently bred in-house. All
rats had an ad libitum access to food and water and were
housed at 22–24 °C under 12 h:12 h light:dark cycle. Rats
were kept separate until six months of age (the start of the
study), then individually for 24 h following surgery and
after that combined in pairs until the end of the study.
The complete study timeline is presented in Fig. 1.
Ab25–35-injected rat model of Alzheimer’s disease. Ab25–35 which has been found in the brains of AD
patients, but not in control samples (Kubo et al., 2002)
and which possess neurotoxic properties of the fulllength Ab42 peptide demonstrated both in vitro (Yankner
et al., 1989; Kowall et al., 1992; Pike et al., 1995;
Sigurdsson et al., 1997; Millucci et al., 2009) and in vivo
(Whitehead et al., 2005; Cheng et al., 2006; Whitehead
et al., 2007; Zussy et al., 2011; Zussy et al., 2013; Yang
et al., 2014; Amtul et al., 2015; Amtul, 2015; Nell et al.,
2015; Nell et al., 2017), was used to model the early stage
of late-onset AD-like pathology in this study. The nontoxic reverse peptide (RP) Ab35–25 was used as a control.
Both peptide fractions were obtained from Bachem Amer-
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icas Inc., Torrence CA. Rats received bilateral ICV injections of either Ab25–35 or RP (500 nmol in 25 lL sterile
0.9% saline).

APP21 TG Fischer 344 rat model of Alzheimer’s
disease. Homozygous APP21 TG rat was developed on
a Fischer 344 background using lentiviral gene therapy
to deliver a human APP gene containing Swedish and
Indiana mutations causally linked to the familial earlyonset form of AD (Agca et al., 2008). Homozygosity was
conﬁrmed by a PCR analysis of the tissue samples from
pups. These rats overexpress a pathogenic human APP
in tissues including the brain and produce high levels of
Ab42 and Ab40 proteins, however, they do not show cerebral amyloid plaques with age, and thus, are a good
model to study prodromal AD pathology (Agca et al.,
2008; Rosen, 2012; Silverberg et al., 2015; Levit et al.,
2017; Klakotskaia et al., 2018; Weishaupt et al., 2018;
Ivanova et al., 2020).

Endothelin-1 (ET-1) model of ischemic stroke. Small
striatal stroke was modeled using a potent
vasoconstrictor agent ET-1 which induced a transient
focal ischemic injury approximately 1 h in duration
(Yanagisawa et al., 1988; Whitehead et al., 2005;
Whitehead et al., 2007; Amtul et al., 2015; Amtul, 2015).
A single injection of Human ET-1 (Sigma-Aldrich Canada
Co., Oakville, ON) was delivered unilaterally into the right
striatum (60 pmol dissolved in 3 lL sterile 0.9% saline).

Surgical procedures
Surgeries were performed under general anesthesia
induced with 3% isoﬂurane (Baxter Corporation,
Mississauga, ON) in oxygen in a Harvard anaesthesia
box (Harvard Apparatus, Holliston, MA) connected to a
tabletop anesthesia machine (VetEquip Inc., Livermore,
CA). Rats were then secured in a stereotaxic surgical
apparatus (David Kopf Instruments, Tujunga, CA) with
continued gas anesthesia. Animals’ body temperature
was maintained at 37 °C for the time of surgery via a
heating pad.
Injection sites for Ab25–35 or RP were identiﬁed using
the coordinates of Bregma ±1.4 mm medial–lateral
(ML), 0.8 mm anterior-posterior (AP) and 4.0 mm
dorsal–ventral (DV) (Paxinos and Watson, 1986). Injections were completed over 20 min per ventricle with an
in situ period of 3 min after each injection. ET-1 or sterile
0.9% saline (Sal; control) injections were administered at
Bregma 3.0 mm ML, +0.5 mm AP and 5.0 mm DV
over 5 min and kept in situ for 3 min post-injection. All
injections were done using a HamiltonÒ syringe (Hamilton
Company, Reno, NV).
Upon completion of stereotaxic injections, rats
received 1 mg/kg of the analgesic buprenorphine
subcutaneously (0.03 mg/ml, Champion Alstoe Animal
Health, Whitby, ON) and 0.03 mL of the antibiotic
enroﬂoxacin intramuscularly (22.7 mg/mL, BaytrilÒ,
Bayer HealthCare Animal Health, Mississauga, ON).
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(Fig. 1). A detailed description of
equipment set up, experimental
procedure protocols and analysis
can be found in a separate
manuscript on the methodology
published by our group (Au et al.,
2016).
Cylinder task. This task was
used for the assessment of
Fig. 1. Timeline for performed behavioral tests and procedures and treatment paradigm. The
forelimb gross motor function
numbers indicate days of the study relative to the surgery day (0). Surgical operations performed on
during spontaneous rearing in a
day 0 as per the assigned treatment group: bilateral intracerebroventricular injection of either Ab25–35
transparent plexiglass cylinder
or reverse peptide (RP, Ab35–25); unilateral striatal injection of either endothelin-1 (ET-1) or 0.9%
saline. Motor tasks: beam-walk (B), cylinder (C) and modiﬁed sticky tape (MST) began with a baseline
apparatus (Schallert et al., 2002).
testing (day -7, -3 and -1, respectively) and were repeated on day 21 for B; days 3 (only for the Ab25–35
It was performed on days -3, 7
– injected rat subset), 7, 20 for C; and days 3, 21 for MST. Morris water maze (MWM) task used to
and 20 after surgery (day 0) for
assess cognitive function was completed after all experimental conditions were surgically induced
both experimental subsets and
(day 0): spatial learning phase was done through days 8–11, two probe trials (Pr) – on days 12 and
additionally on day 3 post-surgery
19, cued trials – on days 20 and 21. The arrows indicate time points of the intraperitoneal
administration of the antioxidant biologic CAT-SKL, a genetically engineered cell penetrating variant
for the Ab25–35 – injected rat subset
of catalase with a serine-lysine-leucine carboxy terminal consensus sequence, or saline. Rats were
(Fig. 1). The task consisted of three
euthanized (E) on day 21 post-surgery, brains were perfused and harvested for immunohistochemical
5-min trials a day with a 20-min
analysis.
inter-trial period. Trials with six or
more forelimb contacts with the
cylinder wall were included in the
CAT-SKL treatment
analysis. The recorded trials were analyzed in iMovie softCAT–SKL (United States patent 7601366 and 8663630
ware (Au et al., 2016). The percentage of aﬀected foreand related international patents) was acquired from
limb (i.e. left forelimb) use was calculated for each
Drs. Paul A. Walton, Stanley R. Terlecky, and Courtney
testing day. The post-surgery results were then divided
R. Giordano. The detailed description of synthesis and
by a pre-surgery baseline value (day -3) to generate an
puriﬁcation of CAT-SKL is presented elsewhere (Wood
aﬀected forelimb use (AFU) score for each testing day
et al., 2006; Koepke et al., 2007; Young et al., 2008;
for each rat individually. An AFU score of 1.0 indicated
Giordano and Terlecky, 2012; Giordano et al., 2015). Wisthe equal use of both limbs. An AFU score of less than
tar rats designated to the CAT-SKL treatment received
1.0 represented a greater use of the unaﬀected limb
1 mg/kg of CAT-SKL intraperitoneally. Rats in the control
and a score of greater than 1.0 signiﬁed the opposite. Pergroup were administered a vehicle treatment of an equivformance each day was presented as an average of three
alent volume of saline solution via the same route. Both
trials of that day (Au et al., 2016).
treatments were given once per week for four consecutive
weeks starting one week prior to the surgery date as
Modified sticky tape task (MST). This task was used
described previously in (Nell et al., 2017) (Fig. 1).
to assess forelimb ﬁne motor and sensory functions
(Sughrue et al., 2006) in the Ab25–35 – injected rat study
Experimental groups
subset on days -1 (baseline), 3 and 21 after surgery
(day 0) with three trials per forelimb per day (Fig. 1).
At the beginning of the study rats were randomly assigned
The MST was completed by wrapping a piece of adhesive
to surgical and treatment groups. Experimental groups
tape (i.e. tactile stimulus) around one of the rat’s forelimbs
and total animal numbers for the ﬁrst study subset using
at a time. A rat was given 45 s to explore the adhesive
the Ab25–35 – injected rat AD model were as follows:
tape. The aﬀected/unaﬀected forelimb ratio was then calRP/Sal + Sal n = 6, ET-1 + CAT-SKL n = 8, ETculated, averaged over trials per day and standardized to
1 + Sal n = 7, Ab/ET-1 + CAT-SKL n = 8, Ab/ETan individual baseline level. An attending to aﬀected fore1 + Sal n = 8. Additionally, Ab + CAT-SKL (n = 8)
limb (AAF) score was generated and the same scoring
and Ab + Sal (n = 9) groups from a previous study
system as for the cylinder task was used.
(Nell et al., 2017) were included in the analysis of cognitive testing. Animal groups in the second study subset
using the APP21 TG Fischer 344 rat model of AD were
WT/Sal n = 8, TG/Sal n = 8, WT/ET-1 n = 9, TG/ET1 n = 8.
Behavioral testing
All behavioral analysis was done by two separate
observers blinded with respect to the rats’ identity (ID)
and experimental group. The testing days for each
behavioral paradigm are depicted on the study timeline

Beam – walk task. This task was implemented to
assess the hindlimb motor function with a coordination
and balance challenge in the Fischer 344 rat subset
(Schallert et al., 2002). Rats underwent the testing on
days -7 and 21 in regard to surgery day 0 (Fig. 1). Brieﬂy,
rats were required to walk across a 1.9 cm wide wooden
beam positioned 40 cm above the ground for three trials in
each direction (a total of six trials). The total number of
steps per trial and number of hindlimb errors (slips or foot
misplacements) per step for each limb were noted from
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the recorded videos in iMovie software (Au et al., 2016).
Left (i.e. aﬀected) hindlimb errors were standardized to
the total number of steps for each testing day. An aﬀected
hindlimb error score (AHE score) was generated for each
rat individually by subtracting the pre-surgery value from
post-surgery value.
Morris water maze (MWM). This task was utilized to
evaluate spatial learning and reference memory
(Vorhees and Williams, 2006; Vorhees and Williams,
2014). Brieﬂy, in this task rats were required to ﬁnd an
escape platform hidden under the water surface of a pool.
Rats were provided with extra-maze cues placed around
the pool for navigation. The platform’s position in the pool,
a quadrant called the target zone (TZ), remained
unchanged during the entire learning period. The platform
was removed from the tank during the probe trial (Au
et al., 2016).
MWM spatial learning phase was completed in 4 days
(days 8–11 post-surgery) with four 90 s – trials per day
separated by a 20 min inter-trial period (Fig. 1). The
probe trials (30 s each) took place on days 12 (Probe 1)
and 19 (Probe 2) to assess short-term and long-term
spatial reference memory, respectively (Fig. 1). After the
end of the day 12 probe the memory was reinforced by
placing the platform back to its original position and
letting the rats sit on it for 10 s. Cued trials were used
as a control for visual impairment (ability to use the
extra-maze cues) and lack of motivation to escape the
pool and occurred on days 20 and 21 (Fig. 1). The
videos were analyzed in ANY-mazeÒ video-tracking
software (Stoelting CO, Wood Dale, IL). Distance and
latency to reach the platform were used as an indication
of spatial and cued learning. Time to ﬁrst entry to the
TZ during the probes was used to assess spatial
memory. Swim speed was also recorded (Au et al., 2016).
Euthanasia and tissue processing
On day 21 post surgery, rats were euthanized by a
euthanyl overdose (Bimeda-MTC Animal Health Inc.,
Cambridge, ON). Rats were then transcardially perfused
with 0.01 M phosphate-buﬀered saline solution (PBS,
pH 7.35) followed by 4% paraformaldehyde (PFA, pH
7.35). Brains were extracted, post-ﬁxed in 4% PFA for
24 h and then stored in 30% sucrose solution until
sliced. Brain tissue was sliced coronally into 35 mm-thick
sections from 3.2 to 4.8 mm relative to Bregma on the
Cryostar NX50 Cryostat (Thermo Fisher Scientiﬁc Inc.,
Waltham, MA) and stored in cryoprotectant solution at
20 °C until immunohistochemical processing.
Immunohistochemistry
Free-ﬂoating brain sections were stained to visualize
activated microglia using a primary antibody directed
against the major histocompatibility complex II (MHC II)
receptor expressed by activated cells (1:1000; OX-6,
RT1B puriﬁed mouse monoclonal; BD PharmingenTM
,
Mississauga, ON). Brieﬂy, sections were ﬁrst washed
with 0.1 M PBS and then sequentially incubated with
following reagents: 1% H2O2 for 10 min at room

temperature (RT), 2% horse serum in 0.1 M PBS with
Triton-X for 1 h at RT, primary antibody buﬀer overnight
at 4⁰C, biotinylated horse anti-mouse secondary
antibody buﬀer (1:500; Vector Laboratories Canada Inc.,
Burlington, ON) for 1 h at RT, 0.05% 3,30 diaminobenzidine tetrahydrochloride (Sigma Aldrich
Canada Co., Oakville, ON) with 1% H2O2. After each
incubation step, sections were washed in 0.1 M PBS
three times for 5 min. Stained sections were mounted
on glass slides using 0.3% gelatin, air-dried overnight,
then dehydrated by sequential immersion in ethanol
solutions of increasing concentration for 5 min each,
cleared in 100% Xylene for 10 min and ﬁnally cover
slipped with Depex media (Electron Microscopy
Sciences, Hatﬁeld, PA, USA).
Imaging and quantiﬁcation
Brain section image acquisition was done on the Nikon
Eclipse Ni-E microscope using NIS-Elements Imaging
Software Version 4.30.02 (Nikon Instruments Inc.,
Melville, NY) using x2 and x10 objective lenses. The
deﬁned regions of interest (ROI) included the striatum
(the infarct area, between Bregma 2.28 mm and
1.44 mm) and the basal forebrain (Bregma 0.96–
0.36 mm). Two independent observers blinded to
experimental conditions and rats’ ID completed the
analysis and quantiﬁcation of inﬂammation visualized by
OX-6 positive microglia using the 64-bit ImageJ
software (Version 1.48u4, Wayne Rasband, National
Institutes of Health, Bethesda, MD). The volume of OX6 inﬂammation in the infarct area in the right striatum
was calculated by the formula: [(ROX-6 immunostained
surface area)  ({n  1}{0.035}{0.315})], where
n = number of immunostained brain sections,
0.035 mm is the thickness of the brain sections and
0.315 mm is the distance between adjacent sections.
OX-6 positive activated microglia cells in the basal
forebrain were manually counted in a predeﬁned ROI
from four consecutive brain sections generating a single
value per animal. These ROI included medial, lateral
and paralambdoid septal nuclei, septohippocampal and
septohypothalamic nuclei, nucleus of the horizontal and
vertical limbs of the diagonal band, lambdoid septal zone.
Statistical analysis
Data analysis was carried out in the GraphPad Prism
software (GraphPad Software Inc., La Jolla, CA) version
6.0 and 8.01 (244). The completed statistical tests
included one-way, two-way and three-way analysis of
variance (ANOVA) followed by a Tukey’s or Bonferroni
multiple comparisons post hoc test. Data are expressed
as the median and interquartile range (25th–75th
percentiles), and a minimum of p  0.05 was
considered statistically signiﬁcant.

RESULTS
The results of two studies on the comorbidity of AD-like
pathology and ischemic stroke are summarized in the
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Table 1. Summary of eﬀects of cerebral Ab25–35 toxicity with ischemic stroke comorbidity on motor function, cognitive function and microglial
inﬂammation and their prevention by CAT-SKL antioxidant treatment. Motor function (MF) was assessed using a cylinder task (gross forelimb MF) and
modiﬁed sticky tape task (ﬁne forelimb MF and sensorium). Cognitive function was assessed in the Morris water maze and parameters included spatial
learning, short-term (probe 1; 24 h after last learning day) and long-term (probe 2; 7 days after probe 1) spatial reference memory, and cued learning.
Microglial inﬂammation was examined in the basal forebrain and right striatum (infarct area) using an immunostaining for the activated microglia marker
OX-6. Eﬀects were assessed via comparison of parameters at individual testing points between groups: for stroke alone (ET-1 + Sal, ET-1 + CATSKL groups) vs control (RP/Sal + Sal) group; for comorbid condition (Ab/ET-1 + Sal, Ab/ET-1 + CAT-SKL groups) vs both stroke groups and vs
control group. Additionally, eﬀects on all parameters except microglia inﬂammation, short-term memory and cued learning were compared between
diﬀerent time points within each experimental group. *Statistically signiﬁcant result (p  0.05). Ab = amyloid b25–35 peptide, CAT-SKL = genetically
engineered cell penetrating variant of catalase with a serine-lysine-leucine carboxy terminal consensus sequence, ET-1 = endothelin-1, RP = reverse
peptide (Ab35–25), Sal = 0.9% saline, Transient deﬁcit – deﬁcit observed at one testing point which then resolved by the end of a test
Stroke condition alone

Ab-toxicity and stroke
comorbidity

Treatment

Saline

CAT-SKL

Saline

CAT-SKL

Experimental group

ET-1 + Sal

ET-1
+ CAT-SKL

Ab/ET-1 + Sal

Ab/ET-1
+ CAT-SKL

Intact
Intact

Transient deﬁcit*
Intact

Intact
Transient deﬁcit*

Intact
Intact

Cued learning

Intact
Intact
Intact
Intact

Intact
Intact
Intact
Intact

Intact
Intact
Impaired*
Intact

Intact
Intact
Prevented*
Intact

Basal forebrain
Right striatum

No change
No change

No change
No change

Increased*
No change

Prevented*
No change

Motor function (MF)

Gross forelimb
Fine forelimb

Cognitive function

Spatial learning
Spatial memory

Microglia activation

Short-term
Long-term

Table 2. Summary of eﬀects of comorbidity of prodromal AD-like pathology with ischemic stroke in APP21 transgenic Fischer 344 rat on motor function,
cognitive function and microglial inﬂammation. Motor function (MF) was assessed using a cylinder task (gross forelimb MF) and a beam-walk task
(gross hindlimb MF, locomotion and gait). Cognitive function was assessed in the Morris water maze and parameters included spatial learning, shortterm (probe 1; 24 h after last learning day) and long-term (probe 2; 7 days after probe 1) spatial reference memory, and cued learning. Microglial
inﬂammation was examined in the basal forebrain and right striatum (infarct area) using an immunostaining for the activated microglia marker OX-6.
Eﬀects were assessed via comparison of parameters at individual testing points between groups including vs control group (WT/Sal). Additionally,
eﬀects on all parameters except microglia inﬂammation, short-term memory and cued learning were compared between diﬀerent time points within
each experimental group. *Statistically signiﬁcant result (p  0.05). APP = amyloid precursor protein, ET-1 = endothelin-1, Sal = 0.9% saline,
TG = APP21 transgenic Fischer 344 rat, WT = wildtype Fischer 344 rat
Prodromal AD alone

Stroke alone

Prodromal AD and
stroke comorbidity

TG/Sal

WT/ET-1

TG/ET-1

Intact
Intact
Intact

Intact
Intact
Intact

Intact
Intact
Impaired*

Cued learning

Intact
Intact
Intact
Intact

Intact
Intact
Intact
Intact

Intact
Intact
Impaired*
Intact

Basal forebrain
Right striatum

No change
No change

No change
No change

No change
Increased*

Experimental group
Motor function (MF)

Gross forelimb MF
Gross hindlimb MF
Balance

Cognitive function

Spatial learning
Spatial memory

Microglial activation

Short-term
Long-term

Table 1 and Table 2 for the Ab25–35 – injected rat model
and APP21 TG Fischer 344 rat model, respectively.

Motor function assessment
Comorbid Ab25–35–injected rats with ET-1 ischemic
stroke did not develop gross forelimb motor
dysfunction and showed only a transient
sensorimotor deﬁcit

Groups that received a stroke or sham stroke with an
exception of ET-1/CAT-SKL rats did not show a
signiﬁcant impairment of a gross forelimb motor function
in the cylinder task, as there was no signiﬁcant
diﬀerence in the AFU scores on post-surgery days
compared to the baseline level (Fig. 2A). ET-1/CAT-SKL
rats were the only group that showed a greater use of
the unaﬀected limb on day 7 post-surgery compared to
the baseline (p = 0.025) and day 3 (p = 0.013).
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Fig. 2. Forelimb motor function of the comorbid Ab25–35 – injected rats with ET-1 ischemic stroke. (A)
Aﬀected forelimb use (AFU) scores for the cylinder task and B) attending aﬀected forelimb (AAF)
scores for the modiﬁed sticky tape (MST) task. The red horizontal dotted line at y = 1.0 indicates an
equal use of or attention paid to the forelimbs. A score of less than 1.0 represented a greater use of/
attention to the unaﬀected limb and a score of greater than 1.0 signiﬁed the opposite. Each bar
represents values standardized to baseline and averaged for three trials per day. Data is presented
as median (25th–75th percentiles). Signiﬁcance is indicated by * in (A) between cylinder task days 7
and 3 for ET-1/CAT-SKL group (p = 0.013) signifying a greater use of unaﬀected limb on day 7
compared to day 3 and in (B) for Ab/ET-1 + Sal vs RP/Sal + Sal in day 3 signifying a less attention
paid to aﬀected limb with the tape in MST (p = 0.022). Repeated measurement two-way ANOVA,
Tukey’s post hoc test, p < 0.05. Ab = amyloid b25–35 peptide, CAT-SKL = genetically engineered
cell penetrating variant of catalase with a serine-lysine-leucine carboxy terminal consensus
sequence, ET-1 = endothelin-1, RP = reverse peptide (Ab35–25), Sal = 0.9% saline.

However, this eﬀect diminished by the last day of testing,
suggesting the improvement of motor function and
compensation of the deﬁcit with time (Fig. 2A).
Additionally, no diﬀerences were observed between the
experimental groups within any of the testing days. The
presence of AD-like pathology did not lead to a worse
motor function in the comorbid Ab25–35 – injected rats
(Ab/ET-1 groups) with or without CAT-SKL when
compared to the stroke condition alone (Fig. 2A).
The ﬁne forelimb motor function and tactile senses
were unchanged following a stroke in all surgical groups
as evidenced by the absence of signiﬁcant diﬀerences
in the AAF scores (time spent attending to aﬀected
forelimb) between the testing days in the MST task
(Fig. 2B). However, when the group performance within
each day was analyzed, comorbid Ab/ET-1 + Sal rats
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paid signiﬁcantly less attention to
the aﬀected limb with the tape on
day 3 post-surgery compared to
control RP/Sal + Sal rats
(Fig. 2B, p = 0.022). This eﬀect
was considered transient since the
scores were no longer diﬀerent
between the groups on day 21
post-stroke.
Comorbid APP21 TG Fischer
344 rats with ET-1 ischemic
stroke showed no forelimb or
hindlimb
gross
motor
dysfunction
As shown in Fig. 3A, APP21 TG
rats recovering from the ischemic
stroke (TG/ET-1 group) did not
experience signiﬁcant forelimb
motor impairment on the cylinder
task, similarly to the comorbid Ab/
ET-1 model. Hindlimb motor
function, which was tested in a
beam-walk task, also appeared to
be unaﬀected with no diﬀerences
in the AHE scores noted between
the groups (Fig. 3B). Rats who
received an ischemic stroke had
overall higher AHE scores (stroke
eﬀect F(1,19) = 4.858, p = 0.04)
suggesting a greater number of
aﬀected foot slips. There was no
additional eﬀect of comorbidity on
the number of foot slips. However,
APP21 TG comorbid rats showed
an increase in total steps during
the walk on day 21 vs baseline
(p = 0.026; Fig. 3C), which
suggested a potential change in
their
balance
when
being
challenged to walk on a beam.
Cognitive function assessment:
MWM

Comorbid Ab25–35 and ET-1
injected rats with intact spatial
learning demonstrated long-term spatial reference
memory impairment that was prevented with the
antioxidant CAT-SKL treatment
All tested groups demonstrated good spatial learning
as indicated by a signiﬁcant decrease in latency and
distance to reach the platform by the end of the training
phase (day 8 vs day 11 p < 0.0001; Fig. 4A, B). All
groups learned to the same extent as there was no
diﬀerence between the groups on each day of learning.
There was no signiﬁcant diﬀerence in swim speed
across all experimental groups on any of the testing
days (Fig. 4C).
On day 12 post-surgery (Probe 1), 24 h following the
last training day, all rats were comparable in the latency
to the ﬁrst entry to the TZ where the platform was
located during the acquisition phase (Fig. 4D). Thus,
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The comorbid TG/ET-1 rats
were able to learn the platform
location well in the spatial learning
phase of the test since they had
signiﬁcantly decreased time and
distance travelled until they found
the platform by the last day of
testing (p < 0.0001) and were
comparable in their performance
to all other groups (Fig. 5A, B).
TG rats had overall a faster
decrease in distance (genotype
F(1.29) = 4.233p = 0.0487,
time  genotype interaction
F(3.87) = 3.320p = 0.024) and
latency to platform (time  gene
interaction
F(3.87)
=
3.475
p = 0.019) with the task
progression. Swim speed during
all four testing days was not
diﬀerent between the groups
(Fig. 5C).
The
TG/ET-1
rats
demonstrated
a
long-term
reference
memory
deﬁcit
(Fig. 5D). The comorbid rats
Fig. 3. Forelimb and hindlimb motor function of the comorbid APP21 TG Fischer 344 rat with ET-1
needed signiﬁcantly more time to
stroke model. (A) Aﬀected (left) forelimb use (AFU) scores for the cylinder task. The red horizontal
reach the TZ on Probe 2
dotted line at y = 1.0 indicates an equal use of the forelimbs. A score of less than 1.0 represented a
compared to Probe 1 (p = 0.03,
greater use of to the unaﬀected limb and a score of greater than 1.0 signiﬁed the opposite. Each bar
Fig. 5D). There was an inter-probe
represents values standardized to baseline and averaged for three trials per day. (B) Aﬀected (left)
hindlimb error scores (AHE score) for the beam walk task. Positive AHE score value represents a
diﬀerence in swim speed noted for
greater number of hindlimb errors made on post-surgery testing day. (C) Total number of steps on the
this group (p = 0.001, Fig. 5C).
beam-walk task. Data is presented as median (25th–75th percentiles). Repeated measurement twoTherefore, to account for this fact,
way and one-way ANOVA, Tukey’s post hoc test, p < 0.05. APP = amyloid precursor protein, ETthe latencies to the TZ entry were
1 = endothelin-1, Sal = 0.9% saline, TG = APP21 transgenic Fischer 344 rat, WT = wildtype
Fischer 344 rat. Signiﬁcance is indicated by * in B) between beam-walk task days -7 and 21 for TG/
ﬁrst standardized to a speed ratio
ET-1 group (p = 0.026).
on both probe days for each rat
individually and then analyzed
statistically. The latencies to ﬁrst
neither stroke or AD pathology alone, nor the comorbidity
entry to the TZ as well as swim speed were similar
of two led to a short-term memory impairment in these
between the experimental groups within each probe day
rats.
(Fig. 5D).
On day 19 (Probe 2), one week following spatial
Both Ab25–35–injected and APP21 TG Fischer 344
learning, comorbid Ab/ET-1 + Sal group was the only
rat models comorbid with ET-1 ischemic stroke
group who required signiﬁcantly more time to enter the
demonstrated good cued learning in the MWM
TZ compared to their Probe 1 (p = 0.028; Fig. 4D).
We did not observe any signiﬁcant diﬀerences
This indicated a disturbance to the long-term memory of
between the RP, Ab25–35 and ET-1 administered groups
the platform location promoted by the co-presence of
when analyzing latency and distance travelled to reach
both stroke and increased cerebral amyloid burden. The
a platform with a ﬁgure mounted on top and above
swim speed measured for both probes was similar and
water level for this task (Fig. 6A, B). Swim speed was
therefore could not account for the detected diﬀerences
also not diﬀerent (Fig. 6C).
(Fig. 4C). Thus, the observed eﬀect was likely due to
Similarly, Fisher 344 rats showed comparable swim
deﬁcits in spatial memory retention and recall as a result
times and distances to cued platform and swim speed
of interaction between cerebral ischemia and amyloid
(Fig. 7). WT and TG rats with stroke overall showed
toxicity. The treatment with CAT-SKL attenuated the
longer latencies (F(1.29) = 7.046 p = 0.013) and
memory deﬁcits in the comorbid condition as no interdistances (F(1.29) = 8.789 p = 0.006) to platform,
probe diﬀerence was seen in the Ab/ET-1 + CAT-SKL
however, swim speed was not diﬀerent from non-stroke
group (Fig. 4D).
animals.
Comorbid APP21 TG Fischer 344 rats with ET-1
These results suggested that all groups in both
ischemic stroke developed long-term spatial
models were equally motivated to ﬁnd the escape
reference memory impairment while showing good
platform and were able to use the cues for spatial
spatial learning of the task
navigation during MWM actual testing.
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Fig. 4. Spatial learning and reference memory in the Morris water maze and the eﬀect of the CAT-SKL treatment in the comorbid Ab25–35 – injected
rats with ET-1 ischemic stroke. (A) Latency and (B) distance travelled to platform during spatial learning phase on days 8–11 post-surgery. (C) Swim
speed for learning and probe days (days 12 and 19). (D) Latency to ﬁrst entry to the target zone (TZ), which contained the hidden platform during the
learning phase, in the probe trials on post-surgery days 12 and 19 as a measure of a short-term and long-term spatial reference memory,
respectively. All values are presented as median (25th–75th percentiles). Repeated measurement two-way ANOVA, Tukey’s and Bonferroni’s (in
(C)) post hoc tests, p < 0.05. Signiﬁcance is represented with * for days 8 vs 11 in all groups in A, B (p < 0.0001) and for an inter-probe diﬀerence in
Ab/ET-1 + Sal group in (D) (p = 0.028); with # for Ab/ET-1 + Sal vs RP/Sal + Sal (p = 0.02), vs ET-1 + CAT-SKL (p = 0.037) and vs Ab + CATSKL (p = 0.047) within day 19. Ab = amyloid b25–35 peptide, CAT-SKL = genetically engineered cell penetrating variant of catalase with a serinelysine-leucine carboxy terminal consensus sequence, ET-1 = endothelin-1, RP = reverse peptide (Ab35–25), Sal = 0.9% saline.
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Fig. 5. Spatial reference memory in the Morris water maze of the comorbid APP21 TG Fischer 344 rat with ET-1 stroke model. (A) Latency and (B)
distance travelled to platform during spatial learning phase on days 8–11 post-surgery. (C) Swim speed for learning and probe days (days 12 and
19). (D) Latency to ﬁrst entry to the target zone (TZ), which contained the hidden platform during the learning phase, in the probe trials on postsurgery days 12 and 19 as a measure of spatial reference memory. Latencies presented as standardized to a speed ratio on both probe days. All
values are presented as median (25th–75th percentiles). Repeated measurement two-way ANOVA, Bonferroni’s post hoc tests, p < 0.05.
Signiﬁcance is represented with * for days 8 vs 11 in all groups in (A), (B) (p < 0.0001); for an inter-probe diﬀerence in TG/ET-1 group in (C)
(p = 0.001) and D (p = 0.03). APP = amyloid precursor protein, ET-1 = endothelin-1, Sal = 0.9% saline, TG = APP21 transgenic Fischer 344
rat, WT = wildtype Fischer 344 rat.
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activation in the basal forebrain,
but not in the striatum CAT-SKL
antioxidant
treatment
ameliorating this pathology
There were no signiﬁcant
diﬀerences in the volume of OX-6
positive microglial inﬂammation in
the right striatum across all groups
(Fig. 8A, D). Thus, the comorbidity
did not result in a greater
inﬂammatory response at the
ischemic lesion site at day 21
post-insult. However, the comorbid
Ab/ET-1 + Sal rats demonstrated
a greater number of OX-6
immunoreactive microglia cells in
the basal forebrain (co-presence
of Ab25–35 with stroke eﬀect; F(1,
= 9.043, p = 0.006)
23)
compared to the stroke condition
alone (vs. ET-1 + Sal p = 0.01,
vs. ET-1 + CAT-SKL p = 0.006;
Fig. 8B, C, E). This increase in
microglia activation in the basal
Fig. 6. Morris water maze cued learning of the comorbid Ab25–35 – injected rats with ET-1 ischemic
stroke. (A) Latency and (B) distance to the hidden platform with a visible cue mounted on top. (C)
forebrain of the comorbid rats was
Swim speed. Data presented as an average of all eight trials across two days of cued learning. Values
attenuated by treatment with the
are presented as the median (25th–75th percentiles). One-way ANOVA, Tukey’s post hoc test,
antioxidant
biologic
CAT-SKL
p < 0.05. Ab = amyloid b25–35 peptide, CAT-SKL = genetically engineered cell penetrating variant of
suggested by the cell counts in
catalase with a carboxy terminal serine-lysine-leucine peroxisomal targeting sequence, ET-1 = endothelin-1, RP = reverse peptide (Ab35–25), Sal = 0.9% saline.
the Ab/ET-1 + CAT-SKL rats,
which were comparable to those
in control and stroke alone groups
Neuroinﬂammation: Microglia activation
(Fig. 8E).
Comorbid
APP21
TG Fischer 344 rats with ET-1
We analyzed the eﬀect of the comorbidity of ischemic
ischemic stroke demonstrated increased microglial
stroke and AD-like pathology in its prodromal and early
activation in the striatal infarct area, but not in the
stages speciﬁcally on microglia activation within the
basal forebrain
cerebral infarct area, the striatum, and the basal
Comorbid TG/ET-1 rats exhibited a signiﬁcantly
forebrain (Figs. 8 and 9).
greater volume of OX-6 positive activated microglia in
Comorbid Ab25–35–injected rats with ET-1
the striatal infarct region compared to their TG
ischemic stroke developed increased microglial

Fig. 7. Morris water maze cued learning of the comorbid APP21 TG Fischer 344 rat with ET-1 stroke model. (A) Latency and (B) distance to the
hidden platform with a visible cue mounted on top. (C) Swim speed during cued trials. Data presented as an average of all eight trials across two
days of cued learning. All values are presented as median (25th–75th percentiles). Repeated measurement two-way ANOVA, Bonferroni’s post hoc
tests, p < 0.05. APP = amyloid precursor protein, ET-1 = endothelin-1, Sal = 0.9% saline, TG = APP21 transgenic Fischer 344 rat,
WT = wildtype Fischer 344 rat.
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Fig. 8. Neuroinﬂammation in the comorbid Ab25–35 – injected rats with ET-1 ischemic stroke and eﬀect of the CAT-SKL treatment. Representative
2 photomicrographs of OX-6 positive activated microglia within (A) the infarct region in the right striatum and (B) basal forebrain. (C) 10 images
of activated microglia from corresponding boxed areas in (B). Scale bar in (A, B) = 1 mm. Scale bar in (C) = 100 lm. (D) Volume of the right striatal
inﬂammation based on the extent of OX-6 immunolabelled microglia. (E) Microglia cell count (cells/optical ﬁeld) in the basal forebrain region. Animal
numbers are as follows: RP/Sal + Sal n = 6, ET-1 + Sal n = 7 (n = 6 in (E)), ET-1 + CAT-SKL n = 8, Ab/ET-1 + Sal n = 8 (n = 6 in (E)), Ab/
ET-1 + CAT-SKL n = 8 (n = 7 in (E)). Values are presented as the median (25th–75th percentiles) and signiﬁcance is represented with * for Ab/
ET-1 + Sal rats vs. ET-1 + Sal (p = 0.01) and ET-1 + CAT-SKL (p = 0.006). One-way ANOVA, Tukey’s post hoc test, p < 0.05. Ab = amyloid
b25–35 peptide, CAT-SKL = genetically engineered cell penetrating variant of catalase with a serine-lysine-leucine carboxy terminal consensus
sequence, ET-1 = endothelin-1, RP = reverse peptide (Ab35–25), Sal = 0.9% saline.
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counterparts (vs TG/Sal p = 0.048, Fig. 9A, D). While this
same volume of inﬂammation was not signiﬁcant
compared to the control WT/Sal group, it was greater
(p = 0.0509, Fig. 9D). The striatal inﬂammation volume
in the stroke alone condition (WT/ET-1 rats) did not
diﬀer signiﬁcantly from sham operated WT or TG rats
(Fig. 9D). Thus, these results demonstrate a synergistic
eﬀect of a stroke within a pre-existing high APP and Ab
cerebral environment on microglia activation in the
ischemic region.
There were no signiﬁcant diﬀerences in the number of
microglia present in the basal forebrain across surgical
groups (Fig. 9B, C, E). The comorbid TG/ET-1 group
tended to have greater levels of activated microglia
compared to WT rats with or without stroke, but this
eﬀect was not signiﬁcant (p = 0.0515 and p = 0.0889,
Fig. 9E). TG rats overall had more OX-6 positive cells
than WT rats (genotype eﬀect F(1.22) = 7.034
p = 0.015, Fig. 9E). This was in contrast to what was
observed in the Ab25–35 infusion rat model of sporadic
AD challenged with striatal stroke described above.

DISCUSSION
The results of this study demonstrate the detrimental
impact of the comorbidity of prodromal (APP21 TG rat)
and more degenerative (Ab25–35 ICV-injected rat) ADlike pathology with ET-1 ischemic stroke on spatial
reference
memory
and
microglia
inﬂammation,
speciﬁcally in the basal forebrain and striatal infarct
zone. This work also shows for the ﬁrst time a
therapeutic potential of the antioxidant biologic CATSKL speciﬁcally in the comorbid AD and stroke condition.
ET-1 – induced ischemic stroke in the striatum, one of
the brain regions involved in motor control, has previously
been shown to produce motor impairment in rat models
(Whitehead et al., 2005; Whitehead et al., 2005). In our
study, stroke alone did not cause a gross impairment in
the limb motor functioning in either model assessed using
the cylinder and beam-walk tests. These tasks have been
used to demonstrate motor dysfunction following a relatively large or multifocal stroke in other models (Clarke
et al., 2007; Clarke et al., 2009; Lipsanen et al., 2011).
It is possible that these tests were not sensitive enough
to detect the possible motor changes caused by a smaller
size striatal lesion which could occur at particular testing
time points after stroke in our study. Although, an overall
stroke eﬀect on the hindlimb function was noted for the
Fischer 344 rat model, no diﬀerence was observed when
comparing performance between individual experimental
groups. However, the comorbid TG rats of prodromal
AD showed diﬃculties with balance suggested by the
increase in total steps on the beam-walk. Interestingly,
clinical studies have also previously indicated that alterations in gait and balance are present early in the disease
process in AD patients, especially when cerebrovascular
pathology is also present (Visser, 1983; Sheridan and
Hausdorﬀ, 2007; Inzitari et al., 2013). More speciﬁc tests
such as the catwalk (Abada et al., 2013; Parkkinen et al.,
2013) would be required to conﬁrm the suggestion of
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potential gait disturbances resulting from the comorbidity
of prodromal AD and stroke.
Somatosensory and especially ﬁne motor deﬁcits
have been previously shown in animal models of stroke
alone and with AD (Whitehead et al., 2005; Clarke
et al., 2007; Cardoso et al., 2013). Analysis of our data
from the MST task indicated only a transient sensorimotor
deﬁcit in the comorbid Ab/ET-1 + Sal rats seen only on
the ﬁrst post-stroke testing day. It is possible that the size
of ischemic lesion produced by striatal stroke in the Ab25–
35 injection AD model was not large enough to cause a
major disruption to somatosensory processes detectable
at this stage of post-stroke recovery. The use of other
speciﬁc tests including corner test and grid walking
(Schaar et al., 2010) could aid in further elucidating the
potential sensorimotor deﬁcits following striatal stroke,
which is important given the connection of the striatum
to the somatosensory cortex.
Diﬃculties with spatial learning have been previously
reported by other groups for rodent models of AD alone
and when AD was paired with an extensive stroke (Choi
et al., 2011; Zussy et al., 2011; Zussy et al., 2013). The
analysis of the MWM task did not reveal any eﬀect of
the comorbidity on learning of the platform location in
either model of AD in the present study. This could be
attributed to a much smaller ischemic lesion limited to
the striatum which could be insuﬃcient to aﬀect spatial
learning or to earlier stages of AD recreated in our rats.
Also, the time course of testing chosen here diﬀers from
aforementioned studies which detected the changes at
later time points of several weeks post-stroke. An
extended testing timeline could be implemented in future
studies to characterize longer-term eﬀects of the comorbid pathology.
There was a signiﬁcant long-term spatial memory
deﬁcit observed in comorbid rats in both the APP21 TG
and Ab25–35 – injected rat models. This was evidenced
by an increase in the swim time to the TZ in search of a
rescue platform, the position of which was learned
earlier in the MWM. The absence of diﬀerences in swim
speed, spatial and cued learning between animal groups
described in the present manuscript and in (Au et al.,
2016) allowed us to be conﬁdent that the observed memory impairment established in the comorbid condition was
likely due to pathological events in the brain areas
involved in spatial memory consolidation and recall. Neither stroke nor AD condition alone demonstrated this deficit, suggesting the potentiating eﬀect of cerebral ischemia
superimposed on a high brain amyloid environment via
shared pathological processes.
Concurrent cerebral administration of Ab25–35 and
striatal stroke resulted in a large increase in OX-6
positive activated microglial cells in the basal forebrain
compared to the stroke only condition. The Ab25–35 –
injected rat was previously reported to show signiﬁcant
OX-6 microgliosis in the basal forebrain which
negatively correlated with cholinergic neuronal loss in
that region and was suggested to be linked to spatial
memory deﬁcits observed in this rat model of AD (Nell
et al., 2015; Nell et al., 2017). Our data further suggest
microglial inﬂammation particularly in the basal forebrain
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as a point of interaction between AD and stroke in the
early disease stage which could lead to earlier establishment of cognitive symptoms in situations when both diseases are present in one individual compared to either
condition alone. Along with the basal forebrain, a region
highly vulnerable to AD, other brain areas implicated in
the memory formation such as hippocampus were shown
to be aﬀected in AD. Ab25–35 – injected rats have been
shown to develop increased gliosis and reduced neuronal
number in the hippocampus (Whitehead et al., 2005; Nell
et al., 2015). Comorbid Ab25–35/ET-1 rats in the present
study could possibly develop an exacerbated hippocampal pathology, which could further contribute to the
observed memory disturbances.
The volume of inﬂammation in the striatal infarct
region of the stroke and Ab25–35 comorbid rats was
unchanged from the level in the stroke alone rats. This
was contrary to the results from earlier studies on threemonth-old comorbid Wistar rats that showed a
progressive increase in infarct size and associated
regional inﬂammation compared to stroke alone rats
who demonstrated a signiﬁcant decrease in microglial
inﬂammation in the infarct region by day 28 after stroke
(Whitehead et al., 2005; Whitehead et al., 2007; Amtul
et al., 2015). This discrepancy could be caused by the difference in the animal’s age at the concurrent presentation
of two insults. It has been shown that microglia cells transition to a chronically hyperactivatated state with
increased age which contributes to formation of aberrant
and persistent inﬂammatory reaction to an insult (Luo
et al., 2010; Krstic and Knuesel, 2013; Perry and
Holmes, 2014; Deleidi et al., 2015). It is possible that
the six-month-old Wistar rats who received ET-1 stroke
could have developed a more profound response to an
ischemic lesion sustained by day 21 after stroke. These
age-related events could blunt the diﬀerence in the OX6 microglial response to stroke alone and to a sudden
amyloid load introduced simultaneously. In addition to
this, we used a higher concentration of ET-1 which could
also have led to a bigger stroke and contributed to a maximized level of regional microgliosis.
On the contrary, the comorbid condition in the TG/ET1
rats resulted in increased levels of activated microglia in
the infarct region compared to TG rats, but not WT/ET-1
rats (stroke alone). Aside from being a diﬀerent strain,
another principal diﬀerence between the APP21 TG
model from the ICV Ab25–35 – injected rats is that there
has already been increased cerebral APP and amyloid
levels preceding the ischemic stroke in the APP21 TG
rats. Developing amyloid pathology in conjunction with
the events occurring during normal brain aging could
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increase brain vulnerability to ischemia and predispose
the brain to a stronger response to stroke, such as the
greater OX-6 microgliosis in the infarct region that was
observed in our comorbid TG rats (Franceschi et al.,
2007; Perry and Holmes, 2014). The striatal pathology
could likely play a role in the motor and memory deﬁcits
seen in this group. This is in line with results of Whitehead
et al., (Whitehead et al., 2007), who reported a cognitive
impairment on the Barnes maze in the comorbid Ab25–
35/ET-1 – injected rats, which had the greatest microgliosis in the striatal infarct zone.
APP21 TG Fischer 344 rats with stroke did not
demonstrate an increase in activated microglia in the
basal forebrain at least at day 21 post-stroke. It remains
a question as to whether this phenomenon could be
established at a later time point in the disease process.
It is possible this model of prodromal AD might show a
diﬀerent pattern of microgliosis involving other brain
areas more susceptible to ischemia in an environment
with pre-existing chronically elevated APP and Ab
levels. In several studies, including those using the
APP21 TG Fischer 344 rats, white matter has been
shown to be particularly vulnerable in AD beginning in
the prodromal stage and undergo pathological changes
including increased microgliosis which were associated
with cognitive impairment (Bilello, 2015; Brickman et al.,
2015; Li et al., 2015; Raj et al., 2017; Weishaupt et al.,
2018; Levit et al., 2019; Ivanova et al., 2020; Levit
et al., 2020). It is possible that, aside from the increased
inﬂammation in the immediate infarct zone, APP21 TG
rats which sustained ischemic brain damage could
develop increased inﬂammation in the white matter tracts
and remote regions connected to the striatum, thus, contributing to memory disturbances observed in comorbid
TG-ET-1 rats.
The present study focused speciﬁcally on microglial
inﬂammation as one of the main and early pathologies
in the disease in two highly vulnerable brain regions.
However, AD is a multifactorial disease aﬀecting
multiple
brain
structures
and
alongside
with
inﬂammation and oxidative stress other events such
synaptic dysfunction and white matter pathology are
implicated in the disease pathogenesis. Therefore,
further investigation is warranted to develop a
comprehensive understanding of the brain changes in
the event of comorbid cerebral ischemia in AD in both
prodromal and early stages. It would also be of a great
importance to characterize the interplay of stroke and
AD in natural conditions occurring with increasing age in
older age animals and at more advanced disease
stages in the future studies. It is also necessary to carry

3
Fig. 9. Neuroinﬂammation: TG/ET-1 comorbid Fischer 344 rat model. Representative 2 photomicrographs of OX-6 positive activated microglia
within (A) the right striatal infarct region and (B) basal forebrain. (C) 10 images of activated microglia presence in the basal forebrain from
corresponding boxed areas in B. Scale bar in A and (B) = 1 mm. Scale bar in (C) = 100 lm. (D) Volume of the right striatal inﬂammation based on
the extent of OX-6 immunolabelled microglia. (E) Microglia cell count (cells/optical ﬁeld) in the basal forebrain region. Values are presented as the
median (25th–75th percentiles) and signiﬁcance is represented with * for TG/ET-1 rats vs TG/Sal (p = 0.048). Overall stroke eﬀect in (D):
F(1.22) = 9.301, p = 0.006. One-way, two-way ANOVA, Tukey’s post hoc test, p < 0.05. ET-1 = endothelin-1, Sal = 0.9% saline, TG = transgenic
(APP21 Fischer 344 rat), WT = wildtype (Fischer 344 rat).
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out the experiments using female rats to elucidate the
potential diﬀerences in eﬀects of the comorbidity on
behavioral and neuropathological aspects between
biological sexes.
This work demonstrates the eﬀectiveness of the
targeted antioxidant CAT-SKL therapy against spatial
memory impairment in a combined in vivo model of
stroke and Ab toxicity. The marked neuroprotective
eﬀect of the CAT-SKL was initially noticed in vitro
(Giordano et al., 2015) and supported by earlier work of
our group using a rat model of AD (Nell et al., 2017). In
the current experiments we demonstrate the ability of
the CAT-SKL treatment to attenuate increased activation
of microglia in the basal forebrain as a result of AD comorbidity with stroke. This data further supports the role of
interdependent oxidative stress and inﬂammation in mediating cognitive dysfunction in a comorbid AD and
ischemic injury condition. The exact mechanism of CATSKL protection is a subject of a separate extensive exploration. One theory could be that the drug is acting through
restoring cellular catalase levels, detoxifying hydrogen
peroxide and subsequently decreasing ROS resulting
from ischemia and AD pathology (Wood et al., 2006;
Koepke et al., 2007; Undyala et al., 2011; Giordano and
Terlecky, 2012; Giordano et al., 2015). Diminished oxidative stress reduces microglia activation and inﬂammatory
damage to cholinergic neurons in the basal forebrain in
particular and thus ameliorates cognitive deﬁcit.
In the present study we have tested a single drug dose
and administration route based on a previous successful
protocol used in vivo (Nell et al., 2017). The treatment
was initiated 1 week before injury, thus being a preventive
measure and potentially increasing brain resilience to an
insult. This could be applied to the clinical situations
involving individuals with early stages of cognitive alterations such as mild neurocognitive disorder or early AD,
who also have a high risk for developing a cerebrovascular accident, a common comorbidity in this age group and
this patient cohort. It remains of great importance to
establish the therapeutic potential of the CAT-SKL biologic in the case of administering it to a pre-existing high
amyloid environment, such as in TG animals, or after
induction of amyloid toxicity and stroke that would represent a more realistic clinical situation. Additionally, a
detailed examination of a therapeutic window and minimum eﬀective dose would also be required to complement the current study and advise on suitability of CATSKL use as a treatment.
In conclusion, this study suggests that microglia
activation in the basal forebrain and infarct area in the
striatum could be one of the pathologies mediating AD
and ischemic stroke interaction and contributing to
spatial memory and motor deﬁcits in case of the
comorbidity starting from the prodromal stage and
continuing into a more advanced stage of AD
development. The antioxidant biologic CAT-SKL showed
a great therapeutic potential for prevention of
exacerbation of inﬂammatory pathology and cognitive
symptoms by the comorbidity of AD and stroke. This
warrants further investigation into its use as a treatment

strategy in individuals with coincidence of dementia and
stroke.

ETHICAL APPROVAL
All animal handling and experimental procedures were
approved by Western University Animal Care
Committee (AUP 2008-113; AUP 2014-016) and were
carried out in accordance with the guidelines of the
Canadian Council on Animal Care and National Institute
of Health Guide for the Care and Use of Laboratory
Animals.

AVAILABILITY OF DATA AND MATERIALS
The datasets supporting the conclusions of this article are
included within the article and its additional ﬁles.

FUNDING
This research was funded by an emerging team grant
from the Canadian Institutes of Health Research (CIHR;
R1478A47) to D. F. C. and CCNA team grant to S. N. W.

ACKNOWLEDGEMENTS
We are grateful to Lynn Wang (University of Western
Ontario, London, Ontario, Canada) for her invaluable
technical assistance. We thank Western University
animal care facility for providing the animal care and
Susanne Schmidt (University of Western Ontario,
London, Ontario, Canada) for the use of behavioral
equipment.

AUTHOR’S CONTRIBUTION
JLM completed acquisition, analysis, and interpretation of
data. NI participated in data analysis, interpretation, and
drafting of the manuscript. HJN acquired and provided
cognitive testing data for a subset of animals. CA and
YA developed the transgenic animal model. CRG
participated
in
CAT-SKL
puriﬁcation
and
characterization.
SRT
and
PAW
developed,
synthesized, puriﬁed and characterized the recombinant
enzyme CAT-SKL. SNW participated in design of the
work, data analysis and interpretation, and supervision
of the work. DFC had primary role in design of the
study, participated in the analysis and interpretation of
the data and the writing of the manuscript and overall
supervision of the work. All authors reviewed and
approved the ﬁnal manuscript.

CONFLICT OF INTERESTS
All authors declare no competing interests associated
with this manuscript.

REFERENCES
Abada Y-se K, Nguyen HP, Schreiber R, Ellenbroek B, Nagai Y
(2013) Assessment of motor function, sensory motor gating and
recognition memory in a novel BACHD transgenic rat model for
Huntington disease. PLoS ONE 8(7):e68584.

J. L. MacKenzie et al. / Neuroscience 487 (2022) 47–65
Agca C, Fritz JJ, Walker LC, Levey AI, Chan AWS, Lah JJ, Agca Y
(2008) Development of transgenic rats producing human bamyloid precursor protein as a model for Alzheimer’s disease:
Transgene and endogenous APP genes are regulated tissuespeciﬁcally. BMC Neurosci 9(1). https://doi.org/10.1186/14712202-9-28.
Akiyama H et al (2000) Inﬂammation and Alzheimer ’s disease.
Neurobiol Aging 21:383–421.
Allen CL, Bayraktutan U (2009) Oxidative stress and its role in the
pathogenesis of ischaemic stroke. Int J Stroke 4(6):461–470.
Amtul Z (2015) Comorbid rat model of ischemia and b-Amyloid
toxicity: Striatal and cortical degeneration. Brain Pathol 25
(1):24–32.
Amtul Z, Nikolova S, Gao L, Keeley RJ, Bechberger JF, Fisher AL,
Bartha R, Munoz DG, McDonald RJ, Naus CC, Wojtowicz JM,
Hachinski V, Cechetto DF (2014) Comorbid Ab toxicity and
stroke: hippocampal atrophy, pathology, and cognitive deﬁcit.
Neurobiol Aging 35(7):1605–1614.
Amtul Z, Whitehead SN, Keeley RJ, Bechberger J, Fisher AL,
McDonald RJ, Naus CC, Munoz DG, Cechetto DF (2015)
Comorbid rat model of ischemia and b-Amyloid toxicity: Striatal
and cortical degeneration. Brain Pathol 25(1):24–32.
Attems J, Jellinger KA (2014) The overlap between vascular disease
and Alzheimer’s disease - lessons from pathology. BMC Med
12:206.
Au JL, Weishaupt N, Nell HJ, Whitehead SN, Cechetto DF (2016)
Motor and hippocampal dependent spatial learning and reference
memory assessment in a transgenic rat model of Alzheimer’s
disease with stroke. J Vis Exp 109.
Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer’s
disease and the basal forebrain cholinergic system: relations toamyloid peptides, cognition, and treatment strategies. Prog
Neurobiol 68:209–245.
Bales KR, Du Y, Holtzman D, Cordell B, Paul SM (2000)
Neuroinﬂammation and Alzheimer’s disease: critical roles for
cytokine/Abeta-induced glial activation, NF-kappaB, and
apolipoprotein E. Neurobiol Aging 21:427–432.
Baudic S, Barba G, Thibaudet M, Smagghe A, Remy P, Traykov L
(2006) Executive function deﬁcits in early Alzheimer ’ s disease
and their relations with episodic memory. Arch Clin
Neurophsychol 21(1):15–21.
Bilello M et al (2015) Correlating cognitive decline with white matter
lesion and brain atrophy MRI measurements in Alzheimer’s
disease. J Alzheimers Dis 48:987–994.
Brickman AM, Zahodne LB, Guzman VA, Narkhede A, Meier IB,
Griﬃth EY, Provenzano FA, Schupf N, Manly JJ, Stern Y,
Luchsinger JA, Mayeux R (2015) Reconsidering harbingers of
dementia: Progression of parietal lobe white matter
hyperintensities predicts Alzheimer’s disease incidence.
Neurobiol Aging 36(1):27–32.
Cardoso MM, Franco ECS, de Souza CC, da Silva MC, Gouveia A,
Gomes-Leal W (2013) Minocycline treatment and bone marrow
mononuclear cell transplantation after endothelin-1 induced
striatal ischemia. Inﬂammation 36(1):197–205.
Caughlin S, Maheshwari S, Agca Y, Agca C, Harris AJ, Jurcic K,
Yeung K-C, Cechetto DF, Whitehead SN (2018) Membrane-lipid
homeostasis in a prodromal rat model of Alzheimer’s disease:
Characteristic proﬁles in ganglioside distributions during aging
detected using MALDI imaging mass spectrometry. Biochim
Biophys Acta - Gen Subj 1862(6):1327–1338.
Cechetto DF, Hachinski V, Whitehead SN (2008) Vascular risk
factors and Alzheimer ’s disease. Expert Rev Neurother 8
(5):743–750.
Cheng G, Whitehead SN, Hachinski V, Cechetto DF (2006) Eﬀects of
pyrrolidine dithiocarbamate on beta-amyloid (25–35)-induced
inﬂammatory responses and memory deﬁcits in the rat.
Neurobiol Dis 23(1):140–151.
Choi B-R, Lee SR, Han J-S, Woo S-K, Kim KM, Choi D-H, Kwon KJ,
Han S-H, Shin CY, Lee J, Chung C-S, Lee S-R, Kim HY (2011)
Synergistic memory impairment through the interaction of chronic

63

cerebral hypoperfusion and amlyloid toxicity in a rat model. Stroke
42(9):2595–2604.
Clarke J, Thornell A, Corbett D, Soininen H, Hiltunen M, Jolkkonen J
(2007) Overexpression of APP provides neuroprotection in the
absence of functional beneﬁt following middle cerebral artery
occlusion in rats. Eur J Neurosci 26(7):1845–1852.
Clarke J, Mala H, Windle V, Chernenko G, Corbett D (2009) The
eﬀects of repeated rehabilitation tune-ups on functional recovery
after focal ischemia in rats. Neurorehab Neural Repair 23
(9):886–894.
Collerton D (1989) Cholinergic function and intellectual decline in.
Neuroscience 19:1–28.
Combs CK, Karlo JC, Kao S-C, Landreth GE (2001) Amyloid
stimulation of microglia and monocytes results in TNFdependent expression of inducible nitric oxide synthase and
neuronal apoptosis. J Neurosci 21:1179–1188.
Craig LA, Hong NS, McDonald RJ (2011) Revisiting the cholinergic
hypothesis in the development of Alzheimer’s disease. Neurosci
Biobehav Rev 35(6):1397–1409.
Del Ser T, Hachinski V, Merskey H, Munoz DG (2005) Alzheimer’s
disease with and without cerebral infarcts. J Neurol Sci 231(12):3–11.
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